dabigatran has been researched along with Recrudescence in 57 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (1.75) | 29.6817 |
| 2010's | 45 (78.95) | 24.3611 |
| 2020's | 11 (19.30) | 2.80 |
| Authors | Studies |
|---|---|
| Bahit, MC; Brainin, M; Brueckmann, M; Cronin, L; Diener, HC; Easton, JD; Granger, CB; Grauer, C; Kleine, E; Lopes, RD; Lyrer, P; Meyerhoff, J; Sacco, RL; Segura, T; Wachter, R | 1 |
| Cai, D; Chen, S; He, J; Huang, P; Lai, Y; Sun, H; Wu, Q; Zhou, L | 1 |
| Albisetti, M; Bomgaars, L; Brandão, LR; Chalmers, E; Felgenhauer, J; Halton, J; Luciani, M; Lvova, O; Mitchell, LG; Saracco, P; Simetzberger, M; Sun, Z; Tartakovsky, I | 1 |
| Atarashi, H; Fukaya, T; Inoue, H; Koretsune, Y; Okumura, K; Taniguchi, A; Uchiyama, S; Yamashita, T; Yasaka, M | 1 |
| Auditeau, C; Blandinières, A; Gendron, N; Smadja, DM; Talbot, A | 1 |
| Bar, M; Bernstein, RA; Brainin, M; Brueckmann, M; Cronin, L; Diener, HC; Donnan, G; Easton, JD; Gdovinová, Z; Granger, CB; Grauer, C; Kleine, E; Kleinig, TJ; Lyrer, P; Martins, S; Meyerhoff, J; Milling, T; Pfeilschifter, W; Poli, S; Reif, M; Rose, DZ; Sacco, RL; Šaňák, D; Schäbitz, WR | 1 |
| Brueckmann, M; Easton, JD; Grauer, C; Lee, BC; Liou, CW; Taniguchi, A; Toyoda, K; Uchiyama, S; Urano, Y; Wong, LKS | 1 |
| D'Elia, E; Di Marco, F; Falanga, A; Gori, M; Grosu, A; Iorio, A; Lorini, FL; Senni, M | 1 |
| de Brouwer, B; Egea, M; Eggington, S; Franco, N; Huynh, M; Ismyrloglou, E; Joglekar, R; Liu, S; Lyon, J; Reynolds, MR; Rosemas, SC; Thijs, V; Tsintzos, SI; Tsivgoulis, G; Witte, KK; Ziegler, PD | 1 |
| Broniatowska, E; Papuga-Szela, E; Undas, A; Weronska, A | 1 |
| Benavente, O; Butcher, K; Coutts, SB; Field, TS; Gioia, L; Hill, MD; Ng, KH; Sharma, M | 1 |
| An, SJ; Kim, CK; Kim, TJ; Ko, SB; Nam, KW; Oh, K; Yoon, BW | 1 |
| Albisetti, M; Biss, B; Bomgaars, L; Brueckmann, M; Gropper, S; Halton, JML; Harper, R; Huang, F; Luciani, M; Maas, H; Mitchell, LG; Tartakovsky, I | 1 |
| Kanai, Y; Matsuda, H; Mitaki, S; Oguro, H; Onoda, K; Tahara, N; Takayoshi, H; Yamaguchi, S | 1 |
| Ageno, W; Barco, S; Binder, H; Brenner, B; Duerschmied, D; Empen, K; Faggiano, P; Ficker, JH; Galiè, N; Ghuysen, A; Held, M; Heydenreich, N; Huisman, MV; Jiménez, D; Klok, FA; Konstantinides, SV; Kozak, M; Lang, IM; Lankeit, M; Meyer, G; Münzel, T; Petris, A; Pruszczyk, P; Quitzau, K; Schellong, S; Schmidt, KH; Stefanovic, BS; Verschuren, F; Wolf-Puetz, A | 1 |
| Abdul-Rahim, AH; Acampa, M; Acciarresi, M; Ageno, W; Agnelli, G; Alberti, A; Athanasakis, G; Bandini, F; Becattini, C; Bellesini, M; Bono, G; Bovi, P; Cappellari, M; Carletti, M; Carolei, A; Caso, V; Chiti, A; Chondrogianni, M; Ciccone, A; Cimini, LA; Colombo, G; Consoli, D; Corea, F; D'Amore, C; De Lodovici, ML; Denti, L; Falocci, N; Flomin, Y; Furie, KL; Galati, F; Gialdini, G; Giannini, N; Giorli, E; Giuntini, M; Gourbali, V; Guideri, F; Karagkiozi, E; Karapanayiotides, T; Kargiotis, O; Lanari, A; Lees, KR; Letteri, F; Liantinioti, C; Lorenzini, G; Lotti, EM; Maccarrone, M; Maimone Baronello, M; Makaritsis, K; Mancuso, M; Marcheselli, S; Martini, G; Masotti, L; Monaco, S; Mosconi, MG; Mumoli, N; Ntaios, G; Orlandi, G; Paciaroni, M; Padovani, A; Pezzini, A; Poli, L; Putaala, J; Sacco, S; Scoditti, U; Silvestrelli, G; Sohn, SI; Soloperto, R; Tadi, P; Tassi, R; Tassinari, T; Tatlisumak, T; Tiseo, C; Tomppo, L; Toni, D; Tsivgoulis, G; Vadikolias, K; Vannucchi, V; Venti, M; Yaghi, S; Zedde, M | 1 |
| Hu, Y; Tang, L; Zhang, Z | 1 |
| Ishikawa, T; Moroi, J; Nakase, T | 1 |
| Fujino, T; Hamai, A; Hara, F; Harada, M; Ikeda, T; Kabuki, T; Ohara, H; Wakakura, S | 1 |
| Fischer, MA; Franklin, JM; Gagne, JJ; Glynn, RJ; Huybrechts, KF; Schneeweiss, S; Wang, SV | 1 |
| Al-Samkari, H; Connors, JM | 1 |
| Carrier, M; Khorana, AA; Lee, AYY; Meyer, G; Noble, S; O'Connell, C; Soff, G | 1 |
| Alings, AMW; Huisman, MV; Klok, FA; Kruip, MJHA; Meijer, K; Simmers, TA; Te Boome, LCJ; Tieleman, R; van den Bemt, B; van der Wall, SJ; van Rein, N; Westerweel, PE | 1 |
| Bernstein, RA; Brueckmann, M; Chernyatina, M; Cotton, D; Cronin, L; Diener, HC; Donnan, G; Easton, JD; Ferro, JM; Granger, CB; Grauer, C; Grond, M; Kallmünzer, B; Kreuzer, J; Krupinski, J; Lee, BC; Lemmens, R; Masjuan, J; Odinak, M; Sacco, RL; Saver, JL; Schellinger, PD; Toni, D; Toyoda, K; Uchiyama, S | 1 |
| Nowak, K; Pac, A; Stepien, K; Undas, A; Zalewski, J | 1 |
| Imberti, D; Mastroiacovo, D; Pomero, F | 1 |
| Baanstra, D; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Kvamme, AM; Mismetti, P; Schellong, S; Schulman, S | 1 |
| Cameron, C; Carrier, M; Castellucci, LA; Clifford, T; Coyle, D; Gandara, E; Le Gal, G; Rodger, MA; Wells, G; Wells, PS | 1 |
| Christiansen, AV; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Le Maulf, F; Mismetti, P; Peter, N; Schellong, S; Schulman, S | 1 |
| Aburakawa, Y; Kimura, T; Kuroda, K; Suzuki, Y; Yahara, O; Yoshida, K | 1 |
| Ansell, J; Mantha, S | 1 |
| Alotaibi, G; Alsaleh, K; Mcmurtry, MS; Wu, C | 1 |
| Black, DF; McBane, RD; Moder, KG; Schaefer, JK; Williams, LN; Wysokinski, WE | 1 |
| Greig, SL; McKeage, K | 1 |
| Feuerstein, JD; Ketwaroo, GA; Leffler, DA; Patwardhan, VR; Sengupta, N; Tapper, EB; Thaker, AM | 1 |
| Eriksson, H; Feuring, M; Goldhaber, SZ; Hantel, S; Kakkar, AK; Kearon, C; Kreuzer, J; Schellong, S; Schulman, S | 1 |
| Bonfanti, C; Franchini, M; Lippi, G | 1 |
| Bnouhanna, W; Cho, TH; Davenas, C; Derex, L; Farghali, A; Mechtouff, L; Nighoghossian, N; Ritzenthaler, T | 1 |
| Chan, EW; He, Y; Lau, WC; Leung, WK; Mok, MT; Tong, TS; Wong, IC | 1 |
| Bächli, E; Walti, C | 1 |
| Kesteven, P; McCaslin, JE; Robertson, L | 1 |
| Browne, C; Cohen, AT; Hamilton, M; Lanitis, T; Leipold, R; Quon, P; Rublee, D | 1 |
| Boehlen, F; Bounameaux, H; Fontana, P; Righini, M; Robert-Ebadi, H | 1 |
| Pickl, S | 1 |
| Arachchillage, DR; Baglin, T; Besser, M; Maclean, R; van Veen, JJ | 1 |
| Kuwashiro, T; Okada, Y; Sahara, N | 1 |
| Milling, TJ; Spyropoulos, AC | 1 |
| Kang, J; Lee, JH; Lee, JS; Lee, KM | 1 |
| Goralczyk, T; Undas, A | 1 |
| Felix, SB; Greinacher, A; Hammer, F; Selleng, K; Wernicke, S | 1 |
| Carrier, M; de Wit, C; Le Gal, G; Shaw, J | 1 |
| Baanstra, D; Eriksson, H; Goldhaber, SZ; Kakkar, AK; Kearon, C; Mismetti, P; Schellong, S; Schnee, J; Schulman, S | 1 |
| Michota, F | 1 |
| Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L | 1 |
| Arnaout, S; Musallam, KM; Rabah, A; Sawaya, FJ; Sawaya, J | 1 |
| Dee, S; Jayathissa, S; Thorne, KM | 1 |
| Amital, H; Furer, A; Karplus, R; Michael, L; Twig, G; Yaniv, G | 1 |
15 review(s) available for dabigatran and Recrudescence
| Article | Year |
|---|---|
[The role of direct oral anticoagulants in the management of cancer-associated thrombosis in 2020].
Topics: Anticoagulants; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cytochrome P-450 Enzyme System; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasm Proteins; Neoplasms; Pyrazoles; Pyridines; Pyridones; Recurrence; Rivaroxaban; Secondary Prevention; Thiazoles; Thrombosis; Venous Thromboembolism | 2020 |
Progress in the research on venous thromboembolism.
Topics: Anticoagulants; Blood Coagulation Factors; Computed Tomography Angiography; Dabigatran; Genetic Predisposition to Disease; Heparin; Humans; Phlebography; Practice Guidelines as Topic; Pulmonary Embolism; Pyridines; Quality of Life; Recurrence; Risk Factors; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2017 |
Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Dabigatran; Glycosaminoglycans; Hemorrhage; Humans; Middle Aged; Pyrazoles; Pyridones; Recurrence; Risk Factors; Rivaroxaban; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2020 |
Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis.
Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Thiophenes; Venous Thromboembolism; Vitamin K | 2013 |
Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Recurrence; Risk Assessment; Rivaroxaban; Survival Analysis; Thiazoles; Venous Thrombosis | 2015 |
Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Chi-Square Distribution; Dabigatran; Hemorrhage; Humans; Morpholines; Odds Ratio; Pyrazoles; Pyridones; Recurrence; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism | 2014 |
Dabigatran etexilate: a review of its use in the treatment of acute venous thromboembolism and prevention of venous thromboembolism recurrence.
Topics: Acute Disease; Administration, Oral; Benzimidazoles; Dabigatran; Humans; Pyridines; Recurrence; Venous Thromboembolism | 2014 |
Cancer-associated thrombosis: investigating the role of new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Recurrence; Thiazoles; Thrombin; Venous Thromboembolism | 2015 |
[Direct acting oral anticoagulants in venous thromboembolism].
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Contraindications; Dabigatran; Drug Interactions; Humans; International Normalized Ratio; Male; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2015 |
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Dabigatran; Factor Xa Inhibitors; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Recurrence; Rivaroxaban; Secondary Prevention; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2015 |
Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
Topics: Anticoagulants; Cost-Benefit Analysis; Dabigatran; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recurrence; Rivaroxaban; Secondary Prevention; United Kingdom; Venous Thromboembolism | 2016 |
Direct oral anticoagulants: a guide for daily practice.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recurrence; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism | 2016 |
[Cerebral infarction and transient ischemic attack].
Topics: Acute-Phase Reaction; Anticoagulants; Cerebral Infarction; Dabigatran; Endovascular Procedures; Factor Xa Inhibitors; Humans; Ischemic Attack, Transient; Japan; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Recombinant Proteins; Recurrence; Rivaroxaban; Tissue Plasminogen Activator; Warfarin | 2016 |
Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed.
Topics: Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Pyrazoles; Pyridones; Recurrence; Risk Assessment; Rivaroxaban; Stroke; Thromboembolism | 2016 |
Intracerebral hemorrhage: Pick your poison.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Chronic Disease; Dabigatran; Humans; Pyrazoles; Pyridones; Recurrence; Risk Assessment; Venous Thromboembolism; Warfarin | 2010 |
13 trial(s) available for dabigatran and Recrudescence
| Article | Year |
|---|---|
Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial.
Topics: Administration, Oral; Age Factors; Aged; Aspirin; Atrial Fibrillation; Body Mass Index; Dabigatran; Double-Blind Method; Embolic Stroke; Female; Humans; Hypertension; Male; Middle Aged; Models, Cardiovascular; Natriuretic Peptide, Brain; Peptide Fragments; Predictive Value of Tests; Recurrence; Risk Factors | 2021 |
Dabigatran versus aspirin for stroke prevention after cryptogenic stroke with patent foramen ovale: A prospective study.
Topics: Aspirin; Dabigatran; Foramen Ovale, Patent; Humans; Ischemic Stroke; Prospective Studies; Recurrence; Risk Factors; Secondary Prevention; Stroke | 2022 |
Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia.
Topics: Child; Dabigatran; Humans; Protein C Deficiency; Recurrence; Risk Factors; Secondary Prevention; Thrombophilia; United States; Venous Thromboembolism | 2022 |
Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups.
Topics: Aged; Aged, 80 and over; Aspirin; Dabigatran; Double-Blind Method; Female; Fibrinolytic Agents; Humans; Intracranial Embolism; Kidney Diseases; Male; Middle Aged; Recurrence; Stroke | 2020 |
Dabigatran or Aspirin in East Asian Patients With Embolic Stroke of Undetermined Source: RE-SPECT ESUS Subgroup Analysis.
Topics: Asia, Eastern; Asian People; Aspirin; Cohort Studies; Dabigatran; Double-Blind Method; Embolic Stroke; Follow-Up Studies; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrence; Treatment Outcome | 2021 |
Dabigatran following acute transient ischemic attack and minor stroke II (DATAS II).
Topics: Administration, Oral; Antithrombins; Cerebral Hemorrhage; Dabigatran; Female; Humans; Ischemic Attack, Transient; Magnetic Resonance Imaging; Male; Recurrence; Sample Size; Stroke; Treatment Outcome | 2017 |
Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability.
Topics: Administration, Oral; Age Factors; Antithrombins; Blood Coagulation; Blood Coagulation Tests; Child; Child, Preschool; Dabigatran; Drug Compounding; Drug Monitoring; Female; Hemorrhage; Humans; Infant; Male; Pulmonary Embolism; Recurrence; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis | 2017 |
Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study.
Topics: Acute Disease; Anticoagulants; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Germany; Hemorrhage; Heparin; Humans; Male; Prospective Studies; Pulmonary Embolism; Recurrence; Reference Standards; Research Design; Risk; Survival Analysis; Treatment Outcome; Young Adult | 2017 |
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.
Topics: Aged; Antithrombins; Aspirin; Dabigatran; Double-Blind Method; Female; Hemorrhage; Humans; Incidence; Intracranial Embolism; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Recurrence; Secondary Prevention; Stroke | 2019 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Intention to Treat Analysis; International Normalized Ratio; Male; Middle Aged; Recurrence; Risk; Venous Thromboembolism; Warfarin; Young Adult | 2013 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Recurrence; Risk Factors; Venous Thromboembolism; Warfarin; Young Adult | 2014 |
Dabigatran versus warfarin in the treatment of acute venous thromboembolism.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; Dabigatran; Double-Blind Method; Female; Humans; International Normalized Ratio; Male; Middle Aged; Pyridines; Recurrence; Risk; Venous Thromboembolism; Warfarin; Young Adult | 2009 |
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Ticlopidine; Treatment Outcome | 2011 |
29 other study(ies) available for dabigatran and Recrudescence
| Article | Year |
|---|---|
Dabigatran for Japanese Patients with Atrial Fibrillation and Prior Stroke: A Subgroup Analysis of the J-Dabigatran Surveillance Program.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Incidence; Ischemic Attack, Transient; Japan; Male; Middle Aged; Population Surveillance; Prospective Studies; Recurrence; Risk Factors; Secondary Prevention; Stroke; Time Factors; Treatment Outcome | 2020 |
An unexpected case of recurrence of pulmonary embolism in a patient recovered from COVID19 in full regimen dose of direct oral anticoagulant drug.
Topics: Administration, Oral; Anticoagulants; COVID-19; Dabigatran; Drug Therapy, Combination; Heparin; Humans; Male; Middle Aged; Pulmonary Embolism; Recurrence; Warfarin | 2021 |
Burden of oral anticoagulation in embolic stroke of undetermined source without atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Clinical Trials as Topic; Cost-Benefit Analysis; Dabigatran; Drug Costs; Embolic Stroke; Hemorrhage; Humans; Ischemic Stroke; Models, Economic; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Time Factors; Treatment Outcome | 2021 |
Nonvitamin K Antagonist Oral Anticoagulant in Patients With Venous Thromboembolism and Polycythemia Vera or Essential Thrombocythemia: A Cohort Study.
Topics: Administration, Oral; Aged; Antithrombins; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Polycythemia Vera; Pyrazoles; Pyridones; Recurrence; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Thrombocythemia, Essential; Time Factors; Treatment Outcome; Venous Thromboembolism | 2021 |
Treatment of Cryptogenic Stroke with Active Cancer with a New Oral Anticoagulant.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Dabigatran; Dalteparin; Disability Evaluation; Enoxaparin; Female; Hemorrhage; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Recurrence; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Seoul; Stroke; Time Factors; Treatment Outcome | 2017 |
Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Japan; Magnetic Resonance Imaging; Male; Pyrazoles; Pyridines; Pyridones; Recurrence; Retrospective Studies; Risk Factors; Rivaroxaban; Secondary Prevention; Stroke; Thiazoles; Time Factors; Treatment Outcome; Warfarin | 2018 |
Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study.
Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Survival Rate; Time Factors; Treatment Outcome; Vitamin K | 2017 |
Outcome of Secondary Stroke Prevention in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Brain Ischemia; Dabigatran; Female; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Pyrazoles; Pyridones; Recurrence; Risk Factors; Rivaroxaban; Secondary Prevention; Stroke; Time Factors; Treatment Outcome; Warfarin | 2018 |
Comparison of Direct Oral Anticoagulants and Warfarin in the Treatment of Deep Venous Thrombosis in the Chronic Phase.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Chronic Disease; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Humans; Male; Pyrazoles; Pyridines; Pyridones; Recurrence; Thiazoles; Treatment Outcome; Ultrasonography; Venous Thrombosis; Warfarin | 2018 |
Generalized boosted modeling to identify subgroups where effect of dabigatran versus warfarin may differ: An observational cohort study of patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Humans; Male; Middle Aged; Models, Biological; Primary Prevention; Recurrence; Secondary Prevention; Stroke; Thromboembolism; Treatment Outcome; Warfarin | 2018 |
Dual anticoagulation with fondaparinux and dabigatran for treatment of cancer-associated hypercoagulability.
Topics: Adult; Anticoagulants; Antithrombins; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Fondaparinux; Humans; Lung Neoplasms; Male; Recurrence; Thrombophilia; Thrombosis; Venous Thromboembolism | 2018 |
Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Dabigatran; Dalteparin; Factor Xa Inhibitors; Hemorrhage; Humans; Multicenter Studies as Topic; Neoplasms; Observational Studies as Topic; Patient Acceptance of Health Care; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Recurrence; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2018 |
Performance of idarucizumab as antidote of dabigatran in daily clinical practice.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Clinical Decision-Making; Dabigatran; Female; Hemorrhage; Hemostasis; Humans; Male; Netherlands; Patient Selection; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Thromboembolism; Time Factors; Treatment Outcome | 2019 |
Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Comparative Effectiveness Research; Dabigatran; Drug Administration Schedule; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Pilot Projects; Prospective Studies; Pyrazoles; Pyridones; Recurrence; Risk Factors; Rivaroxaban; Time Factors; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2019 |
Recurrent ischemic stroke in a patient with the Trousseau syndrome treated with dabigatran.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Heparin, Low-Molecular-Weight; Humans; Male; Recurrence; Stroke | 2014 |
Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Benzimidazoles; beta-Alanine; Cerebral Infarction; Dabigatran; Drug Substitution; Female; Humans; International Normalized Ratio; Lupus Erythematosus, Systemic; Male; Mesenteric Veins; Middle Aged; Morpholines; Portal Vein; Recurrence; Retrospective Studies; Rivaroxaban; Splenic Vein; Stroke; Thiophenes; Thromboembolism; Thrombophilia; Treatment Failure; Venous Thrombosis; Warfarin | 2014 |
The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Enoxaparin; Female; Gastrointestinal Hemorrhage; Heparin; Humans; Ischemic Attack, Transient; Longitudinal Studies; Male; Middle Aged; Morpholines; Patient Readmission; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Venous Thrombosis; Warfarin; Withholding Treatment | 2015 |
Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer.
Topics: Adult; Aged; Anticoagulants; Antithrombins; Dabigatran; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Odds Ratio; Proportional Hazards Models; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Venous Thromboembolism; Warfarin | 2015 |
Safety of early initiation of rivaroxaban or dabigatran after thrombolysis in acute ischemic stroke.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Brain Ischemia; Dabigatran; Drug Administration Schedule; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Intracranial Hemorrhages; Length of Stay; Male; Pilot Projects; Radiography; Recombinant Proteins; Recurrence; Retrospective Studies; Rivaroxaban; Severity of Illness Index; Thrombolytic Therapy; Thrombophilia; Tissue Plasminogen Activator | 2015 |
Prevention of Dabigatran-Related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study.
Topics: Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Hong Kong; Humans; Incidence; Male; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2015 |
[Improving prevention and after-care].
Topics: Aftercare; Anticoagulants; Atrial Fibrillation; Dabigatran; Health Education; Humans; Recurrence; Stroke; Time Factors | 2016 |
Combined factor IIa and Xa inhibitor therapy for thrombosis whilst on therapeutic anticoagulant.
Topics: Adult; Aged; Anticoagulants; Antithrombins; Arginine; Dabigatran; Factor Xa Inhibitors; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Neoplasms; Pipecolic Acids; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Sulfonamides; Venous Thrombosis | 2016 |
Recurrent pulmonary embolism during dabigatran treatment in a patient with immune thrombocytopenic purpura.
Topics: Antithrombins; Dabigatran; Humans; Male; Middle Aged; Platelet Count; Pulmonary Artery; Pulmonary Embolism; Purpura, Thrombocytopenic, Idiopathic; Recurrence | 2016 |
Non-vitamin K antagonist oral anticoagulants in patients with severe inherited thrombophilia: a series of 33 patients.
Topics: Adult; Anticoagulants; Dabigatran; Female; Humans; Male; Medication Adherence; Middle Aged; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Thrombophilia; Venous Thromboembolism; Young Adult | 2017 |
[Recurrent thromboembolisms despite full anticoagulation in a patient with antiphospholipid syndrome].
Topics: Anticoagulants; Antiphospholipid Syndrome; Antithrombins; Dabigatran; Female; Humans; International Normalized Ratio; Lupus Erythematosus, Systemic; Partial Thromboplastin Time; Pulmonary Embolism; Recurrence; Thromboembolism; Venous Thrombosis | 2017 |
Thrombotic and bleeding outcomes following perioperative interruption of direct oral anticoagulants in patients with venous thromboembolic disease.
Topics: Administration, Oral; Aged; Antithrombins; Blood Coagulation; Dabigatran; Drug Administration Schedule; Factor Xa Inhibitors; Female; Half-Life; Humans; Male; Middle Aged; Perioperative Care; Postoperative Hemorrhage; Pyrazoles; Pyridones; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Surgical Procedures, Operative; Time Factors; Treatment Outcome; Venous Thromboembolism | 2017 |
Switching patients from warfarin to dabigatran therapy: to RE-LY or not to rely.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coronary Thrombosis; Dabigatran; Humans; Male; Recurrence; Stroke; Ultrasonography; Warfarin | 2012 |
Thrombotic events after discontinuing dabigatran: rebound or resumption?
Topics: Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Middle Aged; Recurrence; Thrombosis | 2012 |
Dabigatran in recurrent deep vein thrombosis: when one-size does not fit all.
Topics: Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Recurrence; Treatment Failure; Venous Thrombosis | 2012 |